Charles Theuer | executive |
Scott Brown | executive |
Soumit Roy | analyst |
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2023 Earnings Conference Call. [Operator Instructions]
During today's call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, financing opportunities, our development plan and strategies, potential cost savings and other benefits deliverable through our product development platform or PDP, ability to enter into additional license agreements and expectations regarding envafolimab treatments continuing to generate a double-digit objective response rate. These statements are subject to risks and are described in our filings made with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2023, and subsequent reports on Forms 10-Q.
You are cautioned not to place undue reliance on these forward-looking statements unless required by applicable law.